Skip to content

Effects of Shenlingbaizhu powder on the efficacy of chemotherapy and the quality of life of patients with ovarian cancer based on intestinal microecology

Effects of Shenlingbaizhu powder on the efficacy of chemotherapy and the quality of life of patients with ovarian cancer based on intestinal microecology

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004792
Enrollment
Unknown
Registered
2021-04-27
Start date
2021-04-30
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer

Interventions

Sponsors

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. The clinicopathological diagnosis was ovarian cancer; 2. Aged 18 to 65 years; 3. The patients whose survival time was more than 3 months were predicted; 4. We plan to stay in our hospital or chemotherapy for more than 3 cycles, including surgical and non-surgical patients. The operation is palliative resection and postoperative metastasis; 5. Understand and willing to participate in this study, voluntarily sign the informed consent for treatment.

Exclusion criteria

Exclusion criteria: 1. Accompanied by severe infection, high fever, etc; 2. Receiving parenteral nutrition; 3. A large amount of hydrothorax and ascites and severe edema; 4. Patients with cardiovascular and cerebrovascular diseases, liver, kidney, immune and bone marrow dysfunction, psychosis and mental disorders; 5. The cognitive ability of the patients was poor, and they were unable to answer questions or fill in questionnaires.

Design outcomes

Primary

MeasureTime frame
Immune function test;Distribution of intestinal flora;Efficacy evaluation;

Secondary

MeasureTime frame
Quality of life;Cancer fatigue test;Side effects;

Countries

China

Contacts

Public ContactWen Danting

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

wdt850907@163.com+86 13560333505

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026